The iconic rise of Viagra has long been a example of pharmaceutical success, however its future within the broader market now triggers questions about long-term yields . Copycat versions are undercutting exclusivity , causing anxieties that investing in companies heavily reliant to Viagra's former standing could be a dangerous move , especially giv